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SYSTEMATIC REVIEW AND META-ANALYSIS
Future Cardiovascular Disease Risk for 
Women With Gestational Hypertension:  
A Systematic Review and Meta- Analysis
Charmaine Chu Wen Lo , MMed (ClinEpi)*; Andre C. Q. Lo *; Shu Hui Leow; Grace Fisher; Beth Corker, 
BSc; Olivia Batho; Bethan Morris; Monika Chowaniec; Catherine J. Vladutiu, PhD; Abigail Fraser, PhD;  
Clare Oliver-Williams , PhD
BACKGROUND: Inconsistent findings have been found among studies evaluating the risk of cardiovascular disease for women 
who have had pregnancies complicated by gestational hypertension (the new onset of high blood pressure without proteinuria 
during pregnancy). We provide a comprehensive review of studies to quantify the association between gestational hyperten-
sion and cardiovascular events in women.
METHODS AND RESULTS: We conducted a systematic search of PubMed, Embase, and Web of Science in March 2019 for stud-
ies examining the association between gestational hypertension and any cardiovascular event. Two reviewers independently 
assessed the abstracts and full- text articles. Study characteristics and the relative risk (RR) of cardiovascular events associ-
ated with gestational hypertension were extracted from the eligible studies. Where appropriate, the estimates were pooled 
with inverse variance weighted random- effects meta- analysis. A total of 21 studies involving 3 60 1192 women (127 913 with 
gestational hypertension) were identified. Gestational hypertension in the first pregnancy was associated with a greater risk 
of overall cardiovascular disease (RR, 1.45; 95% CI, 1.17–1.80) and coronary heart disease (RR, 1.46; 95% CI, 1.23–1.73), but 
not stroke (RR, 1.26; 95% CI, 0.96–1.65) or thromboembolic events (RR, 0.88; 95% CI, 0.73–1.07). Women with 1 or more 
pregnancies affected by gestational hypertension were at greater risk of cardiovascular disease (RR, 1.81; 95% CI, 1.42–2.31), 
coronary heart disease (RR, 1.83; 95% CI, 1.33–2.51), and heart failure (RR, 1.77; 95% CI, 1.47–2.13), but not stroke (RR, 1.50; 
95% CI, 0.75–2.99).
CONCLUSIONS: Gestational hypertension is associated with a greater risk of overall cardiovascular disease, coronary heart dis-
ease, and heart failure. More research is needed to assess the presence of a dose–response relationship between gestational 
hypertension and subsequent cardiovascular disease.
REGISTRATION: URL: https://www.crd.york.ac.uk/prosp ero/; Unique identifier: CRD42018119031.
Key Words: cardiovascular disease ■ gestational hypertension ■ pregnancy ■ review ■ women
Gestational hypertension (GH), also known as pregnancy- induced hypertension, is defined as the onset of high blood pressure (at least 
140  mm  Hg systolic or 90  mm  Hg diastolic) without 
proteinuria on 2 occasions at least 4  hours apart in 
an ordinarily normotensive pregnant woman after 
20  weeks of gestation.1,2 Rates of GH vary between 
countries, with 1% to 6% of pregnancies complicated 
by GH in Western countries.3,4
Pregnancy- induced hypertension is increasingly 
recognized as a risk factor for subsequent cardio-
vascular disease (CVD) in women.5 In particular, 
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pre- eclampsia, characterized by GH with proteinuria, is 
associated with a markedly higher CVD risk6–8 and has 
been incorporated in the American Heart Association 
guidelines for the assessment of CVD risk in women.9 It 
is unclear if GH and pre- eclampsia are manifestations 
of different severities of the same pathophysiologi-
cal mechanism or represent separate pathologies.10 
Therefore, the raised CVD risk in women with a history 
of pre- eclampsia may not be representative of the risk 
associated with GH.
Studies that have assessed the CVD risk associ-
ated with GH have found mixed results. Results have 
ranged from no raised risk11–13 to more than twice 
the risk of some cardiovascular events.13–18 This lack 
of clarity about the long- term cardiovascular risk for 
women who have had GH without proteinuria is fur-
ther underscored by calls for further research into this 
area by the UK’s National Institute for Health and Care 
Excellence.19 Consequently, we conducted a system-
atic review and meta- analysis of prospective studies 
to evaluate the risk of a range of cardiovascular events 
for women after 1 or more pregnancies complicated 
by GH.
METHODS
The design, implementation, analysis, and reporting 
for this systematic review and meta- analysis are in 
accordance with the Meta- Analysis of Observational 
Studies in Epidemiology20 and Preferred Reporting 
Items for Systematic Reviews and Meta- Analyses21 
protocols (Tables S1 and S2). An internal study 
protocol was developed to perform this review, 
which is registered on PROSPERO (https://www.
crd.york.ac.uk/prosp ero/; review reference number 
CRD42018119031).22 The authors declare that all 
supporting data are available within the article and 
its online supplementary files. 
Search Strategy and Selection Criteria
We searched the databases PubMed, Embase, and 
Web of Science in March 2019. No restrictions were 
applied to the language or publication period of the 
articles. Both medical search headings and open- text 
fields were used to identify articles.
The exposure was GH and any cardiovascular 
outcome was of interest, including (1) overall CVD; (2) 
coronary heart disease (CHD); (3) any stroke, including 
ischemic and hemorrhagic stroke; (4) heart failure; and 
(5) thromboembolic events. The details of the search 
terms are provided in Table S3. The search in PubMed 
was restricted to articles relating to humans. We cross- 
referenced the bibliographies of any relevant journal ar-
ticles and systematic reviews we identified during our 
search to determine if there were any additional stud-
ies not found in our original search that fit our inclusion 
criteria.
To be included in the review, the articles had to 
compare the risk of at least 1 cardiovascular out-
come for women with previous GH with that of 
women who had 1 or more normotensive pregnan-
cies. GH was defined as a new onset of systolic and/
or diastolic hypertension after 20  weeks gestation 
without proteinuria. Events had to occur more than 
1- year postpartum to minimize the risk of comorbid-
ity. Articles only evaluating pre- eclampsia, or com-
bining both pre- eclampsia and GH as an exposure, 
were excluded to minimize heterogeneity in the ex-
posure. Study designs were limited to cohort stud-
ies and case- control studies. Exclusion criteria were 
the following: (1) studies that included animals, men, 
children, or nulliparous women; (2) studies that did 
CLINICAL PERSPECTIVE
What Is New?
• In a systematic review of >3  million women, 
we found that gestational hypertension is as-
sociated with a greater risk of cardiovascular 
disease, coronary heart disease, and heart 
failure.
• Nonsignificant trends toward a greater risk 
of stroke after gestational hypertension were 
found.
What Are the Clinical Implications?
• Women with a pregnancy complicated by ges-
tational hypertension are at greater risk of devel-
oping several different kinds of cardiovascular 
disease.
• Women who experience gestational hyperten-
sion may benefit from counseling during and/
or after pregnancy about their long-term cardio-
vascular risk.
Nonstandard Abbreviations and Acronyms
ARI absolute risk increases




ICD International Classification of Diseases
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not have a cardiovascular outcome; (3) studies that 
combined women with GH and women with pre- 
eclampsia; and (4) studies that did not evaluate GH 
as an independent exposure.
Selection of Studies and Data Extraction
Using the software Abstrackr,23 each abstract found 
with our search strategy were screened by 2 authors 
(C.C.W.L., A.C.Q.L., S.H.L., G.F., B.C., O.B., B.M., or 
M.C.). Any differences between reviewers were dis-
cussed and resolved by a third individual (C.O.- W.). 
For relevant abstracts, full texts were accessed to de-
termine their eligibility for the review. Where 2 studies 
evaluated the same outcome in the same cohort, the 
study with the longer follow- up time was used. Data 
on the follow- up period, study design, population 
characteristics, sample size, exposure and outcome, 
methods of ascertainment for GH and cardiovascu-
lar events, and adjustment factors were abstracted 
and independently verified by a second author. Both 
minimally adjusted and fully adjusted measures of the 
association and 95% CIs were also extracted and 
verified. Any differences between reviewers were dis-
cussed and resolved by a third author.
For the fully adjusted measures of association, 
studies were categorized as poorly, adequately, or 
well adjusted. To be considered well adjusted, stud-
ies had to control for maternal age; socioeconomic 
factors; obstetric history, including pregnancy com-
plications other than GH; and chronic diseases. We 
selected these categories as they broadly cover most 
potential confounders and are representative of the 
range of adjustments made in the studies included 
in the review. Adequately adjusted studies controlled 
for variables from 3 of these 4 categories, and poorly 
adjusted studies controlled for variables in 2 or fewer 
categories.
Two authors independently evaluated the bias within 
each individual study using the validated Newcastle–
Ottawa Scale, a semiquantitative scale designed to 
evaluate the quality of nonrandomized studies.24 It al-
locates a maximum of 9 stars to a study. Study qual-
ity was judged on the selection criteria of participants, 
comparability of groups through adjustment, and ex-
posure or outcome assessment.
Statistical Analysis
The included studies used 2 different approaches to 
classify GH exposure. The first approach classified 
women based on the presence or absence of a di-
agnosis of GH in the first pregnancy. The second ap-
proach classified women as having either a history of 
1 or more pregnancies affected by GH or only having 
normotensive pregnancies. Because of the distinction 
between these 2 classifications, our meta- analyses 
were conducted assessing risk associated with 2 ex-
posures: (1) a diagnosis of GH in the first pregnancy 
and (2) a history of 1 or more pregnancies affected by 
GH.
For a meta- analysis to be conducted, it was nec-
essary to identify a minimum of 3 studies evaluat-
ing the risk of a particular cardiovascular outcome 
(eg, stroke, CHD) associated with 1 of these expo-
sures. If fewer than 3 studies were found for an ex-
posure–outcome combination, then the results were 
included in the systematic literature review, but not in 
the meta- analysis.
For studies that reported separate relative risk (RR) 
estimates for subgroups (eg ethnic groups) or that 
reported CHD and overall stroke risk estimates sep-
arately for the same population, but did not report an 
overall CVD risk estimate, we used inverse variance 
weighted fixed effects meta- analysis to generate over-
all study- level RRs before combining these results with 
those from other studies.
When pooling the results from separate studies, 
the inverse variance weighted method was used 
to combine odds ratio (OR), RR, and hazard ratios 
(HR) to produce a pooled RR under the rare out-
come assumption. Random effects analyses using 
the DerSimonian–Laird model were used to allow 
for between- study heterogeneity as there were clear 
differences between the identified studies, such as 
ethnicity. Heterogeneity was assessed using the 
Cochrane χ2 statistic and the I2 statistic. Individual 
RR estimates and summary estimates were dis-
played graphically with forest plots.
To assess the number of cases that could 
be avoided if effective intervention for CVD are 
targeted to women with GH, the absolute risk 
increases (ARI) for overall CVD and CHD were cal-
culated separately for both exposures. The equation 
ARI=(RR−1)×(assumed control risk) was used, where 
RR is from the meta- analysis. 
Female- specific European Heart Network sta-
tistics for 2015 were used to estimate the assumed 
control risk (ie, the incidence) of overall CVD and 
CHD because the largest number of studies came 
from Europe.25 ARI were expressed as events per 
1000 woman- years of follow- up. It was not possi-
ble to calculate the ARI for heart failure or throm-
boembolic events as we could not obtain estimates 
of their incidence. The ARI was not calculated for 
stroke because of the nonsignificant results in the 
main meta- analyses.
Sensitivity Analyses
A number of sensitivity analyses were conducted. The 
first analysis excluded studies with the largest effect 
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magnitude of the pooled result and the observed het-
erogeneity. The second analysis included all studies 
and reran all meta- analyses with fixed effects models. 
This was performed because the DerSimonian–Laird 
method for random effects meta- analysis may have 
statistical limitations in the case of few studies.26 
Therefore a fixed effects meta- analysis will provide an 
assessment of the consistency of the results and an 
estimation of the relationships specifically in the over-
all populations studied. Several studies assessed the 
risk of stroke subtypes (intracerebral hemorrhage and 
ischemic stroke) associated with a history of GH. To 
assess the risk of any stroke outcome, an additional 
meta- analysis was conducted that combined risk es-
timates for overall stroke and stroke subtypes associ-
ated with a history of GH.
A total of 5 stratified analyses were conducted to 
evaluate (1) the effect of different levels of adjustment, 
(2) the potential impact of bias in individual studies, and 
(3) the effect of study- level characteristics on the asso-
ciation between GH and overall CVD. Only overall CVD 
was assessed as an outcome because too few studies 
were included in the meta- analyses of other events. 
Analyses were stratified by (1) level of adjustment, (2) 
risk of bias, (3) duration of follow- up, (4) year of publica-
tion, and (5) the population studied. In these analyses, 
we tested for trend across strata using random effects 
meta- regression.
Small study effects were evaluated through funnel 
plots and Egger tests for meta- analyses including 6 or 
more studies.27 Upon evidence of funnel plot asym-
metry and indication of significant bias from the Egger 
test, the trim- and- fill method was used to correct for 
funnel plot asymmetry.28
All tests were 2- tailed and P values of <0.05 were 
considered statistically significant. STATA software 
package (version 14.2; Stata Corp, College Station, 
TX) was used for all statistical analyses.
Figure  1. Identification of studies included in the review of GH and risk of 
cardiovascular events.
GH indicates gestational hypertension. 
Identified and screened, after removing duplicates (n=6974)
PubMed search (n=4302)
Embase search (n=1664)
Web of Science search (n=1037)
Bibliographic search (n=2)
Excluded during initial screen for violating 
inclusion criteria (n=6882) 
Screened in full test review (n=92)
Excluded (n=71)
GH is not the exposure (n=16)
No cardiovascular events (n=14)
Events occur in the 1st post-partum year (n=5)
Irrelevant study design (n=1)
Irrelevant population (n=2)
A review / conference abstract (n=19)
No measure of association (n=4)
Duplicate populations (n=10)
Included in final review (n=21)
Studies evaluating GH in the first pregnancy (n=10)
Studies evaluating a history of GH (n=11)
Included in the meta-analysis (n=19)
Studies evaluating GH in the first pregnancy (n=9)
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RESULTS
Our search strategy identified 6974 studies, of which 
6882 were excluded during the initial abstract screen. 
The remaining 92 articles were reviewed in full, result-
ing in 71 being excluded and 21 included in our final 
review (Figure  1). The studies included 3  601  192 
women, with 127  913 women with a history of 1 or 
more pregnancies affected by gestational hyperten-
sion from 18 cohort studies11–13,29–39 and 3 nested 
case- control studies.15,18,40 Studies were conducted in 
Europe (12 studies*) and North America (5 stud-
ies15,17,31,32,36) as well as in Taiwan (2 studies18,41) and 
Australia (1 study13) (Table).
All of the studies ascertained GH and cardiovas-
cular events through medical records, registry data, 
or health insurance claims (Table, Table S4). The du-
ration of follow- up varied from a median of 4.5 years16 
to a maximum of 73  years17 (Table). Based on the 
Newcastle–Ottawa scale, 5 studies were judged to be 
at high risk of bias, and 10 studies provided risk esti-
mates that were poorly adjusted (Tables S5 and S6).
GH in the First Pregnancy 
A total of 11 studies,11,12,14,31,33,34,36–40 including 
3 209 836 women (74 066 with GH), examined the risk 
of cardiovascular events in women whose first preg-
nancy was affected by GH. The risk of the following 
events was assessed: overall CVD, CHD, heart failure, 
any stroke, myocardial infarction (MI), thromboembolic 
events, angina, other circulatory disease, and a com-
bined outcome of acute MI and acute cerebral stroke 
(Figure 2, Tables S7 and S8). Of the 9 included cohorts, 
GH affected 1.0% to 27.1% of first pregnancies. Meta- 
analyses included 2 818 819 women (66 130 with GH) 
for overall CVD, 1 793 887 women (35 876 with GH) for 
CHD, 1 402 870 women (27 940 with GH) for stroke, 
and 1 402 870 women (27 940 with GH) for thrombo-
embolic events.
Meta- analyses of adjusted estimates found a sig-
nificantly greater risk of overall CVD (7 stud-
ies11,12,14,31,34,36,37; RR, 1.45; 95% CI, 1.17–1.80) and CHD 
(4 studies11,34,37,39; RR, 1.46; 95% CI, 1.23–1.72), but 
not overall stroke (3 studies11,34,37; RR, 1.26; 95% CI, 
0.96–1.64) or thromboembolic events (3 studies11,34,40; 
RR, 0.88; 95% CI, 0.73–1.07) (Figure 3). There was ev-
idence of significant between- study heterogeneity for 
overall CVD (I2=92%, P<0.001), CHD (74%, P=0.009), 
and overall stroke (82%, P=0.004), but not thrombo-
embolic events (0%, P=0.413). Meta- analyses of the 
unadjusted results were consistent with these findings 
(Figure S1).
The ARI in overall CVD and CHD associated with 
GH in the first pregnancy, based on the European 
population, were 8.6 and 4.2 events per 1000 woman- 
years, respectively.
Five findings from 3 studies were not included in 
the meta- analyses (Table S8). These studies evalu-
ated heart failure, a composite outcome of MI and 
acute cerebral stroke, angina, MI, and other circula-
tory disease. Greater risks of heart failure and com-
bined acute MI and acute cerebral stroke were noted, 
which both attenuated after adjustment (adjusted 
HR, 1.37; 95% CI, 0.98–1.93; and adjusted HR, 1.8; 
95% CI, 0.8–4.1), respectively.34,38 One study found 
no increased risk of MI (adjusted OR, 0.73; 95% CI, 
0.32–1.63) or angina (adjusted OR, 1.02; 95% CI, 
0.58–1.81), but noted a greater risk of other circula-
tory disease, defined as circulatory diseases that did 
not include hypertension, CHD, or cerebrovascular 
disease (adjusted incident rate ratio [IRR], 1.51; 95% 
CI, 1.06–2.14).40
History of GH
A total of 11 studies from 10 populations† assessed the 
risk of a cardiovascular outcome associated with a his-
tory of 1 or more pregnancies affected by GH. They 
included 2 291 304 women (73 994 with GH). The stud-
ies evaluated overall CVD, CHD, heart failure, overall 
stroke, intracerebral hemorrhage, ischemic stroke, MI, 
and thromboembolic events (Figure 1, Tables S7 and 
S8). Of the included studies, 9 were cohort studies in 
which the prevalence of women with a history of GH 
ranged from 1.1% to 19.0%. Meta- analyses included 
861  087 women (50  356 with GH) for overall CVD, 
471 454 women (35 272 with GH) for CHD, 1 126 452 
women (16 800 with GH) for heart failure, and 463 911 
women (34 281 with GH) for stroke.
In meta- analyses of adjusted risk estimates, a his-
tory of GH was associated with a greater risk of overall 
CVD (8 studies13,15–18,29,32; RR, 1.81; 95% CI, 1.42–
2.32), CHD (4 studies13,17,29,35; RR, 1.83; 95% CI, 1.33–
2.51) and heart failure (3 studies13,17,29; RR, 1.77; 95% 
CI, 1.47–2.13), but not overall stroke (3 studies29,30,35; 
RR, 1.50; 95% CI, 0.75–2.99) (Figure  4). There was 
evidence of high heterogeneity in all analyses: overall 
CVD (84%, P<0.001), CHD (88%, P<0.001), heart fail-
ure (63%, P=0.065), and overall stroke (70%, P=0.035). 
A greater CVD risk was also observed in the meta- 
analysis of unadjusted findings (Figure S2).
The ARI in overall CVD and CHD associated with 
a history of GH, based on the European population, 
were 15.6 and 7.6 events per 1000 woman- years, 
respectively.
Findings from 7 studies were not included in the 
meta- analysis (Table S8). These studies evaluated 
the risk of MI, intracerebral hemorrhage, ischemic 
stroke, cardiomyopathy, and thromboembolic events. 
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Evidence of higher risks were found for cardiomyopa-
thy (HR, 1.83; 95% CI, 1.20–2.63), intracerebral hemor-
rhage (IRR, 3.62; 95% CI, 3.63–3.81) and, in 2 studies, 
ischemic stroke (IRR, 1.59; 95% CI, 1.24–2.04; HR, 
2.78; 95% CI, 1.13–6.82).16,30,35,41 A history of GH was 
also associated with MI in 1 study (IRR, 1.75; 95% CI, 
1.40–2.19),35 but not in a second study (HR, 1.41; 95% 
CI, 0.19–10.21).16 No statistically strong evidence of an 
association between a history of GH and thromboem-
bolic events was found (HR, 1.5; 95% CI, 0.9–2.5).15
Two studies assessed the dose–response relationship 
between number of pregnancies with GH and a cardio-
vascular outcome. Both identified cohorts of women with 
2 pregnancies who were categorized as having (1) GH in 
the first pregnancy only, (2) GH in the second pregnancy 
only, (3) GH in both pregnancies, or (4) GH in neither preg-
nancy. A greater risk of overall CVD relative to normoten-
sive women was found for women with GH in their first 
pregnancy (HR, 1.7; 95% CI, 1.5–2.0), their second preg-
nancy (HR, 2.4; 95% CI, 2.1–2.8), and in both pregnancies 
(HR, 1.9; 95% CI, 1.8–2.0).37 A greater CHD risk was also 
noted for women with GH in either their first pregnancy 
(IRR, 1.9; 95% CI, 1.5–2.4) or second pregnancy (IRR, 2.4; 
95% CI, 1.8–3.2) and for those with 2 or more affected 
pregnancies (IRR, 2.8; 95% CI, 2.0–3.9).39
Sensitivity Analyses
Risk estimates were consistent after excluding studies 
with the largest effect and after conducting a fixed ef-
fects meta- analysis, with I2 results staying relatively con-
stant (Table S9). When all stroke events, including overall 
stroke and stroke subtypes (intracerebral hemorrhage 































































































































































































































































































































































































































































































































































































































































































































































Figure  2. Association between gestational hypertension 
and cardiovascular events, showing summary RRs for the 
meta- analyses of each outcome.
RR indicates relative risk.
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meta- analysis, there was evidence for a greater risk of 
any stroke outcome for women with 1 or more preg-
nancies affected by GH: RR, 1.96 (95% CI, 1.06–3.63). 
Evidence for between- study heterogeneity was found in 
this analysis (98%, P<0.001) (Figure S3). 
The overall CVD analyses were separately stratified 
by average duration of follow- up, risk of bias, level of 
adjustment, year of publication, and population (Table 
S10). There was no evidence that risk estimates varied 
between strata, and there remained evidence of het-
erogeneity in most categories after stratification.
Small Study Effects
The funnel plot for overall CVD risk after GH in the first 
pregnancy did not show evidence of asymmetry (Egger 
test, P=0.935) (Figure S4). The funnel plot for a history 
of GH and overall CVD risk indicated potential asym-
metry (P=0.051), with publications of small studies with 
null or negative effect estimates missing (Figure S5). 
Use of the trim- and- fill method resulted in a RR of 1.26 
(95% CI, 1.15–1.39). The funnel plot for a history of GH 
and risk of any stroke outcome did not show evidence 
of asymmetry (P=0.382) (Figure S6).
DISCUSSION
This systematic review found that women previously 
diagnosed with GH had a greater risk of overall CVD, 
CHD, and heart failure and some indication of a greater 
risk of stroke as well.
Figure  3. Association between gestational hypertension in a woman’s first pregnancy and 
subsequent risk of cardiovascular events in adjusted analyses.
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This study adds to the literature on the relationship 
between women’s obstetric history and risk of car-
diovascular events. A single previous review evalu-
ated cardiovascular events after GH42; however, they 
focused on morbidity from CVD and cerebrovascu-
lar disease only. Our findings substantially build on it 
providing a comprehensive, holistic review of the risk 
of fatal and nonfatal cardiovascular events after GH.
This study adds to the growing literature on the 
relationship between women’s obstetric history and 
their subsequent risk of cardiovascular events. These 
include a greater risk of overall CVD with recurrent mis-
carriages,43 preterm birth,44 fetal growth restriction,45 
and pre- eclampsia.46 The magnitude of association for 
overall CVD risk found in the current review is similar 
to that found with recurrent miscarriages,43 preterm 
birth44 and fetal growth restriction.45 Although the over-
all CVD risk associated with pre- eclampsia is greater 
than that of GH.46
Strengths and Weaknesses of the Study
Strengths of this study include the large number of 
women included and the variety of cardiovascular 
events assessed, which allowed us to obtain the most 
holistic picture to date of the effect of GH on long- term 
cardiovascular health. Because of the larger number 
of studies included in the overall CVD analysis, it was 
possible to assess the impact of study characteristics 
Figure  4. Association between a history of one or more pregnancies affected by gestational 
hypertension and subsequent risk of cardiovascular events in adjusted analyses.
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on the meta- analysis and to conduct sensitivity analy-
ses. Furthermore, there was sufficient follow- up dura-
tion in many of the studies (10 studies had more than 
15 years of follow- up) for long- term CVD risk to be ad-
equately assessed. Lastly, diagnoses of GH and car-
diovascular events were mainly ascertained through 
medical records, which reduced possible information 
bias arising from self- report.
Nevertheless, our study has limitations. First, it is 
possible that despite searching multiple databases 
without language or time restrictions, relevant studies 
were missed. Second, there were only 21 studies iden-
tified, and at most 8 studies were included in any sin-
gle meta- analysis, suggesting that analyses could be 
influenced by a single study. However, exclusion of the 
studies with the largest effect estimates did not mate-
rially alter the conclusions of the meta- analyses. Few 
studies were found for some events, such as stroke 
and thromboembolic events, and thus limited sensitiv-
ity analyses. 
Third, high heterogeneity (I2>70%) was found for 
most meta- analyses. This may be attributed to differ-
ences in study design, methodology, or population. 
Stratified analyses in the current review were limited 
to CVD only and may have been underpowered to de-
tect some of these differences. Other potential sources 
of heterogeneity include differences in the frequency 
of postpartum chronic hypertension and variation in 
outcome and exposure identification. Chronic hyper-
tension is likely to be an important mediator of the 
relationship between GH and CVD,40,47 therefore the 
frequency of conversion of GH to chronic hypertension 
may be a source of heterogeneity between populations 
and thus studies. Outcome definitions may have varied 
between studies because of the inclusion of different 
International Classification of Diseases (ICD) codes 
to define the same outcome (Table S4).  Although all 
studies used robust measurements of exposure or 
events through blood pressure measurement and reg-
istries, revisions of ICD criteria could have led to differ-
ences in the definition of ICD codes between studies. 
Furthermore, there are challenges in identifying ex-
posed women as well, as it requires a blood pressure 
measurement taken before 20 weeks gestation to rule 
out chronic hypertension, the criteria for which has 
changed over time, notably in the United States.48
Fourth, many studies were of poor quality, and 
there were different adjustment sets considered, which 
could have resulted in residual confounding. However, 
when low- quality studies were excluded, the results 
were broadly similar. Fifth, our funnel plot for overall 
CVD risk with a history of GH indicates some asymme-
try where small studies that report a significant, pos-
itive result are more likely to be published (Figure S4). 
Use of the trim- and- fill method found that the associ-
ation would remain after correcting for the asymmetry. 
Lastly, the majority of studies were from Western pop-
ulations, which may limit the generalizability of these 
findings to other populations.
Implications for Clinical Practice
Several theories have been proposed to explain 
the link between GH and the development of CVD. 
Hypertension in pregnancy may cause lasting damage 
that contributes to CVD. Alternatively, or in addition 
to this, women who develop GH may have a pre- 
existing predisposition to CVD, which unmasks itself 
during pregnancy. For example, prepregnancy body 
mass index is particularly important for GH risk,49 and 
body mass index, in general, is linked to CVD devel-
opment.50,51 These theories, in combination with the 
findings of this review, underscore the importance of 
intervention to decrease CVD risk factors. This could 
have the dual benefit of decreasing both the severity 
and incidence of GH and CVD. 
The timing of when an intervention is administered 
merits discussion, and the pathological mechanisms 
linking GH to CVD development have implications for 
this. If there is a pre- existing predisposition to CVD, 
then intervention before conception should be a pri-
ority. There is increasing emphasis on the importance 
of preconception health and its implications for future 
health.52 However, the challenges of intervening before 
conception lie in identifying women considering preg-
nancy and will not aid women with unplanned preg-
nancies, which may be up to half of all pregnancies in 
some groups of women.53
Intervention during or shortly after pregnancy may 
be a viable approach and may help mitigate any long- 
term damage caused by GH. Strategies for manag-
ing cardiovascular risk factors during pregnancy could 
include lifestyle changes that limit excess gestational 
weight gain, a known risk factor for GH and other preg-
nancy complications.54,55 There is evidence that life-
style changes can be effective in mitigating maternal 
and fetal risks,56 and research is underway to identify 
the ideal interventions.57 Women who experience GH 
may also benefit from counseling during and/or after 
pregnancy about their long- term cardiovascular risk. 
Strategies that could be implemented after pregnancy 
may include discussion of heart age calculations,58,59 
which may be more applicable to a younger popula-
tion of women than predicting their cardiovascular risk, 
which is likely to be low in the years after giving birth.
Unanswered Questions and Future 
Research
Pre- eclampsia is currently recognized in guidelines 
for assessing CVD risk in women9; however, GH is 
not. To assess whether GH should also be included 
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The risk of some diseases that have been evaluated 
in relation to GH, such as stroke subtypes, would 
benefit from further study to confirm the associa-
tion indicated in this review, whereas many cardio-
vascular events have been entirely overlooked, such 
as peripheral arterial disease and transient ischemic 
attack. Furthermore, only 2 studies were identified 
that assessed a dose–response relationship, that is, 
whether the risk of a cardiovascular outcome rises 
with an increasing number of pregnancies affected 
by GH. Given the evidence for a dose–response re-
lationship for both preterm birth and pre- eclampsia, 
whereby CVD risk is greater with the number of 
affected pregnancies,60,61 the limited evaluation 
of a dose–response relationship for GH needs 
addressing.
CONCLUSIONS
In conclusion, we found that GH is associated with 
a greater risk of overall CVD, specifically CHD and 
heart failure. The greater risk associated with many of 
these events is similar to other pregnancy complica-
tions, such as preterm birth and fetal growth restric-
tion. Women who experience GH should be aware of 
this greater risk and may benefit from prenatal and 
postnatal counseling to increase their awareness of 
strategies that can reduce their CVD risk during and 
after birth.
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Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
5, Fig 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
5, 9-13, Tables 
S4, S5 & S7 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  Tables S6 & 
S10 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
Table S8 & S9, 
Fig 3 & 4 Fig 
S1, S2 & S3 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  Fig 2, 3 & 4 Fig 
S1, S2 & S3 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  5, 7,Table S11, 
Fig S4, S5 & S6 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).  6-7, Table S9 & 
S10 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
7-9 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
8 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.  7-9 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 









Table S2. MOOSE Checklist for Meta-analyses of Observational Studies. 
Item No Recommendation 
Reported on 
Page No 
Reporting of background should include 
1 Problem definition 3 
2 Hypothesis statement 3 
3 Description of study outcome(s) 3 
4 Type of exposure or intervention used 3 
5 Type of study designs used 3 
6 Study population 3 
Reporting of search strategy should include 
7 Qualifications of searchers (eg, librarians and investigators) 4 
8 Search strategy, including time period included in the synthesis and key words 3 
9 Effort to include all available studies, including contact with authors 3 
10 Databases and registries searched 3 
11 
Search software used, name and version, including special features used (eg, 
explosion) 
3-4 
12 Use of hand searching (eg, reference lists of obtained articles) 3 
13 List of citations located and those excluded, including justification Figure 1 
14 Method of addressing articles published in languages other than English None found 
15 Method of handling abstracts and unpublished studies None found 
16 Description of any contact with authors 
None 
required 
Reporting of methods should include 
17 
Description of relevance or appropriateness of studies assembled for assessing the 
hypothesis to be tested 
5 
18 








Assessment of confounding (eg, comparability of cases and controls in studies where 
appropriate) 
4, Table S5 
21 
Assessment of study quality, including blinding of quality assessors, stratification or 
regression on possible predictors of study results 
4, Table S4, 
TableS 9 
22 Assessment of heterogeneity 4 
23 
Description of statistical methods (eg, complete description of fixed or random effects 
models, justification of whether the chosen models account for predictors of study 
results, dose-response models, or cumulative meta-analysis) in sufficient detail to be 
replicated 
4 
24 Provision of appropriate tables and graphics 
Fig 1, Tables 
S1-S7  
Reporting of results should include 
25 Graphic summarizing individual study estimates and overall estimate 
Fig 2-4, Fig 
S1,S2 
















28 Indication of statistical uncertainty of findings 
Fig 2-4, Fig 
S1, S2 
Reporting of discussion should include 
29 Quantitative assessment of bias (eg, publication bias) 8, Fig S4-S6 
30 Justification for exclusion (eg, exclusion of non-English language citations) n/a 
31 Assessment of quality of included studies 
8, Table S6-
S7 
Reporting of conclusions should include 
32 Consideration of alternative explanations for observed results 8-9 
33 
Generalization of the conclusions (ie, appropriate for the data presented and within the 
domain of the literature review) 
8 
34 Guidelines for future research 9 








Table S3. PubMed Search Strategy. 
Population ("humans"[MeSH Terms] OR "Women"[Mesh] OR "Female"[Mesh] OR "Pregnancy"[Mesh]) AND 
Exposure ("Hypertension, Pregnancy-Induced"[Mesh] OR “Gestational hypertension*”[All Fields] OR “Pregnancy 
Induced Hypertension*”[All Fields] OR “Transient Hypertension* in Pregnancy”[All Fields]) AND 
Outcome (“Acute Coronary Syndrome”[All Fields] OR “Aneurysm”[All Fields] OR “Angina”[All Fields] OR “Aortic 
Stenosis”[All Fields] OR “Aortic Stenoses”[All Fields] OR “Aortic Valve Insufficienc*”[All Fields] OR 
“Aortic Valve Stenosis”[All Fields] OR “Aortic Valve Stenoses”[All Fields] OR “Arrhythmia*”[All Fields] 
OR “Atrial Fibrillation*”[All Fields] OR “Atrial Flutter*”[All Fields] OR “Bradycardia”[All Fields] OR 
“Cardiac Arrest*”[All Fields] OR “Cardiac Oedema”[All Fields] OR “Cardiac edema”[All Fields] OR 
“Cardiac Tamponade”[All Fields] OR “Cardiomegal*”[All Fields] OR “Cardiomyopath*”[All Fields] OR 
“Cardiovascular Disease*”[All Fields] OR “CVD”[All Fields] OR “Cerebrovascular Disease*”[All Fields] 
OR “Cerebrovascular Disorder*”[All Fields] OR “Cerebral infarction*”[All Fields] OR “Cerebral 
haemorrhage*”[All Fields] OR “Cerebral hemorrhage*”[All Fields] OR “Commotio Cordis”[All Fields] OR 
“Coronary Artery Disease*”[All Fields] OR “Coronary Disease*”[All Fields] OR “CHD”[All Fields] OR 
“Coronary Occlusion*”[All Fields] OR “Coronary Restenosis”[All Fields] OR “Coronary Restenoses”[All 
Fields] OR “Coronary Stenosis”[All Fields] OR “Coronary Stenoses”[All Fields] OR “Coronary 
Vasospasm”[All Fields] OR “Emboli”[All Fields] OR “Embolism”[All Fields] OR “Endocarditis”[All Fields] 
OR “Heart Arrest*”[All Fields] OR “Heart Attack*”[All Fields] OR “Heart Block*”[All Fields] OR “Heart 
Disease*”[All Fields] OR “Heart Failure*”[All Fields] OR “Heart Rupture*”[All Fields] OR “Heart Valve 
Disease*”[All Fields] OR “Heart Valve Prolapse*”[All Fields] OR “Hypertroph*”[All Fields] OR 
“Intracranial Haemorrhage*”[All Fields] OR “Intracranial Hemorrhage*”[All Fields] OR “Long QT 
Syndrome”[All Fields] OR “Mitral Valve Insufficienc*”[All Fields] OR “Myocardial Infarction*”[All Fields] 
OR “Myocardial Ischemia”[All Fields] OR “Myocardial Ischaemia”[All Fields] OR “Myocardial 
Reperfusion Injury”[All Fields] OR “Myocardial Stunning”[All Fields] OR “Paroxysmal Dyspnea”[All 
Fields] OR “Peripheral arterial disease”[All Fields] OR “Pre-Excitation Syndrome”[All Fields] OR 
“Pulmonary Valve Insufficiency”[All Fields] OR “Pulmonary Valve Stenosis”[All Fields] OR “Pulmonary 
Valve Stenoses”[All Fields] OR “Pulmonary Heart Disease”[All Fields] OR “Stroke”[All Fields] OR 
“Sudden Cardiac”[All Fields] OR “Subarachnoid haemorrhage”[All Fields] OR “Subarachnoid 
hemorrhage”[All Fields] OR “Tachycardia”[All Fields] OR “Thrombosis”[All Fields] OR “Thromboses”[All 
Fields] OR “Transient Ischaemic Attack”[All Fields] OR “Transient Ischemic Attack”[All Fields] OR 
“Tricuspid Valve Insufficiency”[All Fields] OR “Tricuspid Valve Stenosis”[All Fields] OR “Tricuspid Valve 
Stenoses”[All Fields] OR “Ventricular Dysfunction”[All Fields] OR “Ventricular Fibrillation”[All Fields] 
OR “Ventricular Flutter”[All Fields] OR "Acute Coronary Syndrome"[Mesh] OR "Aneurysm"[Mesh] OR 
"Angina Pectoris"[Mesh] OR "Aortic Valve Stenosis"[Mesh] OR "Aortic Valve Insufficiency"[Mesh] OR 
"Arrhythmias, Cardiac"[Mesh] OR "Atrial Fibrillation"[Mesh] OR "Atrial Flutter"[Mesh] OR 
"Bradycardia"[Mesh] OR "Heart Arrest"[Mesh] OR "Edema, Cardiac"[Mesh] OR "Cardiac 
Tamponade"[Mesh] OR "Cardiomegaly"[Mesh] OR "Cardiomyopathies"[Mesh] OR "Cardiovascular 
Diseases"[Mesh] OR "Cerebrovascular Disorders"[Mesh] OR "Commotio Cordis"[Mesh]) OR 
"Coronary Artery Disease"[Mesh] OR "Coronary Disease"[Mesh] OR "Coronary Occlusion"[Mesh] OR 
"Coronary Restenosis"[Mesh] OR "Coronary Stenosis"[Mesh] OR "Coronary Vasospasm"[Mesh] OR 
"Embolism"[Mesh] OR "Endocarditis"[Mesh] OR "Myocardial Infarction"[Mesh] OR "Heart Block"[Mesh] 
OR "Heart Diseases"[Mesh] OR "Heart Failure"[Mesh] OR "Heart Rupture"[Mesh] OR "Heart Valve 
Diseases"[Mesh] OR "Heart Valve Prolapse"[Mesh] OR "Hypertrophy"[Mesh] OR "Intracranial 
Hemorrhages"[Mesh] OR "Long QT Syndrome"[Mesh] OR "Mitral Valve Insufficiency"[Mesh] OR 
"Myocardial Ischemia"[Mesh] OR "Myocardial Reperfusion Injury"[Mesh] OR "Myocardial 
Stunning"[Mesh] OR "Dyspnea, Paroxysmal"[Mesh] OR "Peripheral Arterial Disease"[Mesh] OR "Pre-
Excitation Syndromes"[Mesh] OR "Pulmonary Valve Insufficiency"[Mesh] OR "Pulmonary Valve 
Stenosis"[Mesh] OR "Pulmonary Heart Disease"[Mesh] OR "Stroke"[Mesh] OR "Death, Sudden, 
Cardiac"[Mesh] OR "Subarachnoid Hemorrhage"[Mesh] OR "Tachycardia"[Mesh] OR 
"Thrombosis"[Mesh] OR "Ischemic Attack, Transient"[Mesh] OR "Tricuspid Valve Insufficiency"[Mesh] 
OR "Tricuspid Valve Stenosis"[Mesh] OR "Ventricular Dysfunction"[Mesh] OR "Ventricular 
Fibrillation"[Mesh] OR "Ventricular Flutter"[Mesh]) AND 
Study 
Design 
(“longitudinal studies"[MeSH Terms] OR “longitudinal study”[All Fields] OR “longitudinal studies”[All 
Fields] OR "prospective"[All Fields] OR “cohort”[All Fields] OR “cohorts”[All Fields] OR “follow up”[All 
Fields] OR “follow-up”[All Fields] OR "Epidemiology"[Mesh] OR "Epidemiology"[All Fields] OR 
"Epidemiological"[All Fields] OR "Retrospective Studies"[Mesh] OR "Retrospective"[All Fields] OR 
“prospective”[All Fields] OR "Cross-Sectional Studies"[Mesh] OR "Cross-Sectional"[All fields] OR 









Table S4. Definitions of Cardiovascular Events.  
 
First author, year Definition 
Andolf et al. 201730 
Coronary Heart Disease: ICD-10 (I20-25) 
Stroke: ICD-10 (I60-69) 
Heart Failure: ICD-10 (I50) 
Behrens et al. 201631 
Congestive Heart Failure: ICD-8 (427.09-427.19, 427.99, 428.99, 782.49); ICD-10 (I50.0-50.9); 
Cardiomyopathy: ICD-8 (425.99); ICD-10 (I42.0-43.8, O90.3) 
Bhattacharya et al. 
201211 
CHD: ICD-9 (410-4, 428);  ICD-10 (I20-5, I50);  
Stroke: ICD-9 (430-8); ICD-10 (I60-9);  
CVD: ICD-9 (390-459); ICD-10 (I00-I99, G45) 
Cain et al. 201632 
CVD: ICD-9 codes for CHD, cerebrovascular disease, peripheral artery disease, or congestive heart failure, or for cardiac 
or peripheral arterial revascularization that were not specified 
Cirillo et al. 201533 CVD mortality: ICD-7 (420.1); ICD-8 (410, 412); ICD-9 (410, 411, 414, 429), ICD-10 (I21, I24, I25) 
Grandi et al. 201714 
CVD: Read codes for cerebrovascular disease, CHD, coronary revascularization, MI, peripheral arterial disease, transient 
ischaemic attack and stroke 
Kestenbaum et al. 
200315 
Thromboembolism: ICD-9 (451.1, 453, 415.1); 
CVD: ICD-9 (410, 430, 431, 434, 436), coronary artery revascularization procedure, including coronary artery bypass 
grafting (procedure code:36) 
Lin et al. 201629 Intracerebral haemorrhage: ICD-9 (430–432)   
Luoto et al. 200812 CVD: ICD-9 (389-459); ICD-10 (I00-I99) 
Lykke et al. 200935 
CHD: ICD-8 (410-414), ICD-10 (I20-I25); 
Heart Failure: ICD-8 (42709-42711, 42719, 42799, 42899, 42900, 42908, 42909), ICD-10 (I50, I51.3, I51.9) 
Thromboembolic event: ICD-8 (444, 450-1), ICD-10 (I26, I74, I82) 
Stroke: ICD-8 (430-438), ICD-10 (I60-I67, G45) 
Lykke et al. 201034 CVD: ICD-8 (39-44, 451-458), ICD-10 (DI0-DI9) 
Männistö et al. 201336 CHD, MI, Heart failure, Ischemic stroke: ICD codes, which were not specified  
Ray et al. 200537 CVD: ICD-9, ICD-10 codes, which were not specified 
Riise et al. 201838 
CVD: ICD-9 (390–459); ICD-10 (I00–I99, except I84); 
CHD: ICD-9 (410–414); ICD-10 (I20–I25);  
Stroke: ICD-9 (430–438); ICD-10 (I60–I69) 
Riise et al. 201939 
Acute MI or acute cerebral stroke - composite of hospitalization with AMI: ICD-9 (410); ICD-10 (I21-22); death from CHD: 









Schmiegelow et al. 
201416 
MI: ICD-10 (I21-I22); 
CVD: ICD-10 (I00-I99); 
Ischemic stroke: ICD-10 (I63-I64). 
Theilen et al. 201617 
CVD: ICD-9 (390–459);  
CHD, Stroke: Codes not specified 
Tooher et al. 201713 CHD, Stroke: ICD-9 & ICD-10 codes, which weren’t specified  
Wikstrom et al. 200540 CHD: ICD-9 (410–414), ICD-10 (I20–I25) 
Wilson et al  200341 
Angina, MI, DVT: ascertained through the women’s general practitioner, medical and death records  
Other circulatory disease: ICD-9 (390-8, 405, 415-27, 440-59), ICD-10 (I00-9, I15, I26-8, I30-49, I51-2, I70-99) 
Yeh et al. 201418 CVD, ICD-9 (390-459) 









Table S5. Risk of Bias Assessment in Prospective Studies. 
 
First author, year Selection Comparability Outcome Overall Assessment 
Andolf et al. 2017 30 ★★★ ★★ ★★ Low Risk of Bias   
Behrens et al. 201631 ★★★★ ★★ ★★★ Low Risk of Bias   
Bhattacharya et al. 201211 ★★★ ★★ ★★ Low Risk of Bias   
Cain et al. 201632 ★★★★ ★★ ★★ Low Risk of Bias 
Cirillo et al. 201533 ★★★★ ★★ ★★★ Low Risk of Bias   
Grandi et al. 201714 ★★★★ ★★ ★ High Risk of Bias  
Kestenbaum et al. 2003 15 ★★★★ ★★ ★ High Risk of Bias  
Lin et al. 201629 ★★★★ ★ ★ High Risk of Bias  
Luoto et al. 200812 ★★ ★★ ★ ★ Moderate Risk of Bias   
Lykke et al. 200935 ★★★★ ★★ ★★ Low Risk of Bias   
Lykke et al. 201034 ★★★★ ★★ ★★ Low Risk of Bias   
Männistö et al. 201336 ★★★ ★★ ★★ Low Risk of Bias   
Ray et al. 200537 ★★★★ ★★ ★★ Low Risk of Bias   
Riise et al. 201838 ★★★★ ★★ ★★★ Low Risk of Bias   
Riise et al. 201939 ★★★★ ★★ ★★★ Low Risk of Bias   
Schmiegelow et al. 201416 ★★★★ ★★ ★★ Low Risk of Bias   
Theilen et al. 201617 ★★★★ ★★ ★ High Risk of Bias 
Tooher et al. 201713 ★★★ ★★ ★ High Risk of Bias  
Wikstrom et al. 200540 ★★★★ ★★ ★★ Low Risk of Bias   
Wilson et al. 200341 ★★★ ★★ ★★ Low Risk of Bias   
Yeh et al. 201418 ★★★★ ★ ★★ Low Risk of Bias   









Table S6. Adjustments of Included Studies. 
 
First author, year Adjustment factors Quality of adjustment  
Andolf et al. 201730 
Mother's age at birth, mother's attained educational level in 1985, marital status and origin (Nordic/non‐
Nordic), history of cardiovascular disease later in life (diabetes, arteriosclerosis, stroke, ischemic heart 
disease, heart failure and hypertension) 
Adequate 
Behrens et al. 201631 Maternal age, maternal birth year, parity, multiple pregnancy and stillbirth Poor 
Bhattacharya et al. 201211 Year of birth, social class and smoking Poor 
Cain et al. 201632 
Age, race/ethnicity, nativity, education, income, 5-year history of hyperlipidemia, migraine, lupus; pre-
pregnancy BMI, gestational diabetes, tobacco use, drug use, and infant sex 
Well 
Cirillo et al. 201533 Age, race, parity, BMI, and cigarette smoking Well 
Grandi et al. 201714 
Age, smoking, BMI, excessive alcohol use, year of cohort entry, region of residence, multiple gestation 
at first pregnancy, depression, dyslipidaemia, venous thromboembolism, polycystic ovary syndrome, 
gestational diabetes (measured between 12 weeks of gestation and 6 weeks post‐partum), diabetes 
mellitus, renal disease, migraines, family history of hypertension and family history of cardiovascular 
disease any time before cohort entry, number of distinct drug classes prescribed, and use of statin, 
aspirin and anti‐depressant medications in the year prior to pregnancy 
Well 
Kestenbaum et al. 200315 Age, parity, calendar year of delivery Poor 
Lin et al. 201629 Age, follow-up years Poor 
Luoto et al. 200812 Age, hormone use, height, marital status and visit to private doctor Adequate 
Lykke et al. 200935 
Age, year of delivery, preterm delivery, SGA offspring, placental abruption, stillbirth and later type 2 
diabetes mellitus 
Adequate 
Lykke et al. 201034 Age, year of delivery. Poor 
Männistö et al. 201336 
Age at pregnancy, pre-pregnancy BMI, smoking, parity, diabetes mellitus before/during pregnancy, 
socioeconomic status 
Well 
Ray et al. 200537 
Age, multiple gestation, length of stay, income quintile, rural residence, drug dependence, and 
gestational diabetes mellitus in index delivery, and hypertension, any diabetes mellitus, obesity, 
dyslipidaemia, tobacco use, renal disease, migraine headache, and systemic lupus erythematosus 
Well 
Riise et al. 201838 Age, educational level, marital status, and birth year of first child Poor 
Riise et al. 201939 
Age at recruitment  age at first delivery, education (primary, high school/vocational, any college/ 
university) and a family history of MI prior to age 60 
Well 
Schmiegelow et al. 201416 Age, smoking, and year of inclusion Poor 
Theilen et al. 201617 
Age, year of childbirth, parity, infant sex, parental education, preterm delivery, race-ethnicity, maternal 
marital status 
Adequate 








Wikstrom et al. 200540 Age, socio‐economic level and category of hospital Poor 
Wilson et al. 200341 * Age, BMI, social class, and smoking habit. Adequate 
Yeh et al. 201418 Age, diabetes, dyslipidemia, incident hypertension, date of delivery Poor 










Table S7. Results of Studies Included in the Meta-analysis by Outcome. 





Unadjusted or Age-adjusted Results Adjusted Results * 
Cardiovascular 
Disease 
Bhattacharya et al. 201211 GH in 1st pregnancy 1,319 IRR 1.19 (1.06,1.34) 1.25 (1.11,1.41) 
Cain et al. 201632 GH in 1st pregnancy 2447 HR 1.18 (1.01, 1.37) 0.99 (0.85, 1.16) 
Grandi et al. 201714 GH in 1st pregnancy 920 † HR 2.4 (1.9, 3.1) 2.3 (1.8, 2.9) 
Luoto et al. 200812 GH in 1st pregnancy 38 HR 0.87 (0.61, 1.25) 0.90 (0.62, 1.30) 
Lykke et al. 201034 GH in 1st pregnancy 1,194 HR NG 2.47 (1.74, 3.52) 
Ray et al. 200537 GH in 1st pregnancy 1,987 HR NG 1.8 (1.4, 2.2) 
Riise et al. 201838 GH in 1st pregnancy 19,869 HR 1.8 (1.7, 2.0)   1.8 (1.7, 2.0)  
Cirillo et al. 2015 ‡33 A history of GH 9,000 † HR 
African American: 1.70 (1.10, 2.65) 
non-African American: 0.90 (0.63,1.36) 
African American: 1.8 (1.09, 2.82) 
non-African American: 1.0 (0.68, 1.52) 
Kestenbaum et al. 200315 A history of GH 83 HR 2.9 (1.8, 4.9) 2.8 (1.6, 4.8) 
Luoto et al. 200812 * A history of GH 98 HR 1.18 (0.99, 1.40) 1.17 (0.98, 1.41) 
Schmiegelow et al. 201416 A history of GH 374 HR NG 2.77 (1.47, 5.21) 
Theilen et al. 201617 A history of GH NG HR NG 2.39 (1.78, 3.21) 
Yeh et al. 201418 A history of GH 182 HR NG 2.00 (1.26, 3.18) 
Coronary Heart 
Disease 
Bhattacharya et al. 201211 GH in 1st pregnancy 681 IRR 1.09 (1.00,1.19) 1.22 (1.11, 1.34) 
Lykke et al.200935 GH in 1st pregnancy 2,271 HR 1.67 (1.41, 1.97) 1.48 (1.25, 1.76) 
Riise et al. 201838 GH in 1st pregnancy 2,364 HR 1.7 (1.3, 2.2) 1.7 (1.3, 2.1) 
Wikstrom et al. 200540 GH in 1st pregnancy 2,142 IRR 2.0 (1.7, 2.5) 1.6 (1.3, 2.0) 
Andolf et al. 2017 30 § A history of GH 10,755 † HR 1.33 (1.20, 1.48) 1.26 (1.13, 1.40) 
Männistö et al. 201336 A history of GH 1,225 HR NG 1.44 (1.24, 1.68) 
Tooher et al. 201713 § A history of GH NG OR NG 3.19 (2.11, 4.83) 
Theilen et al. 201617 A history of GH NG HR NG 2.77 (1.62, 4.75) 
Stroke ‖ 
Bhattacharya et al. 201211 GH in 1st pregnancy 2,638 IRR 0.97 (0.86,1.09) 1.04 (0.91,1.18) 
Lykke et al. 200935 GH in 1st pregnancy 8,987 HR 1.68 (1.42, 1.97) 1.51 (1.26, 1.81) 
Riise et al. 201838 GH in 1st pregnancy 2,452 HR 1.3 (0.9, 1.7) 1.3 (0.9, 1.7) 
Andolf et al. 2017 30 § A history of GH 7,436 † HR 1.36 (1.20, 1.55) 1.30 (1.14, 1.48) 
Tooher et al. 201713 § A history of GH NG OR NG 0.57 (0.14, 2.31) 
Theilen et al. 201617 A history of GH NG HR NG 2.97 (1.49, 5.92) 
Heart Failure 
Andolf et al. 2017 30 A history of GH 3,165 † HR 1.62 (1.36, 1.93) 1.52 (1.28, 1.80) 
Männistö et al. 201336 A history of GH 486 IRR NG 1.79 (1.43, 2.21) 










Bhattacharya et al. 201211 GH in 1st pregnancy 384 IRR 0.82 (0.65,1.04) 0.86 (0.67,1.09) 
Lykke et al. 200935 GH in 1st pregnancy 3,881 HR 1.01 (0.72-1.40) 1.03 (0.73, 1.45) 
Wilson et al. 200341 GH in 1st pregnancy 47 OR NG 0.65 (0.35, 1.20) 
GH – gestational hypertension; NG – not given; HR – Hazard Ratio, OR – Odds Ratio, IRR – incident rate ratio  
* See Table S4 for adjustment; † estimated; ‡ Results were combined by fixed effect meta-analysis to provide an estimate of the CVD risk for the whole population. 
§ CHD and stroke results for each paper were combined by fixed effect meta-analysis to provide an estimate of the risk of CVD. ‖ Studies that reported all-cause 









Table S8. Results of Studies Not Included in the Meta-analysis by Outcome. 
Outcome First author, year Exposure definition Cases (N) 
Point 
Estimate 
Unadjusted Results Adjusted Results * 
Heart Failure Lykke et al 200935 GH in 1st pregnancy 7,483 HR 1.57 (1.12-2.20) 1.37 (0.98-1.93) 
Angina Wilson et al. 200341 GH in 1st pregnancy 64 OR NG 1.02 (0.58 to 1.81) 
Acute MI and 
acute cerebral 
stroke 
Riise et al. 201939 GH in 1st pregnancy 134 HR 2.4 (1.1-5.5) 1.8 (0.8-4.1) 
Other circulatory 
disease † 
Wilson et al. 200341 GH in 1st pregnancy 172 IRR NG 1.51 (1.06-2.14) 
Myocardial 
Infarction 
Wilson et al. 200341 GH in 1st pregnancy 30 OR NG 0.73 (0.32-1.63) 
Männistö et al. 201336 A history of GH 471 IRR NG 1.75 (1.40–2.19) 
Schmiegelow et al. 
201416 
A history of GH 68 HR NG 1.41 (0.19-10.21) 
Intracerebral 
haemorrhage 
Lin et al. 201629 A history of GH 27 IRR NG 3.72 (3.63-3.81) 
Ischaemic Stroke 
Männistö et al. 201336 A history of GH 384 IRR NG 1.59 (1.24-2.04) 
Schmiegelow et al. 
201416 
A history of GH 175 HR NG 2.78 (1.13-6.82) 
Cardiomyopathy Behrens et al. 201631 A history of GH 1,448 HR NG 1.83 (1.20-2.63) 
Thromboembolic 
event 
Kestenbaum et al. 
200315 
A history of GH 127 HR 1.4 (0.8-2.4) 1.5 (0.9-2.5) 
Cardiovascular 
Disease 
Riise et al. 201838 
Pregnancies with 
GH in women with 
2+ pregnancies 
19,869 HR NG 
GH 1st pregnancy: 1.7 (1.5–2.0)  
GH 2nd pregnancy: 2.4 (2.1–2.8)  
2+ GH pregnancies: 1.9 (1.8–2.0)  
Coronary Heart 
Disease 
Wikstrom et al. 200540 
Pregnancies with 
GH in women with 
2+ pregnancies 
1,242 IRR 
GH 1st pregnancy: 1.9 (1.5-2.4) 
GH 2nd pregnancy: 2.7 (2.0–3.5) 
2+ GH pregnancies: 3.3 (2.4–4.5) 
GH 1st pregnancy: 1.9 (1.5-2.4)  
GH 2nd pregnancy: 2.4 (1.8–3.2)  
2+ GH pregnancies 2.8 (2.0–3.9)  
GH – gestational hypertension; MI – myocardial infarction; NG – not given; HR – Hazard Ratio, OR – Odds Ratio, IRR – incident rate ratio  









Table S9. Sensitivity Analyses of Risk of Cardiovascular Events Estimated from the Adjusted Meta-Analyses. 
 
Outcome Exposure Sensitivity Analysis Excluded Studies RR  (95% CI) I2 (95% CI) 
Cardiovascular 
Disease 
GH in 1st pregnancy 
   Excluding study(s) with the largest effect  Grandi 201714 1.35 (1.08-1.69) 92% (86-96%) 
   Fixed effects model n/a 1.52 (1.44-1.61) 92%  (87-96%) 
A history of GH 
   Excluding study(s) with the largest effect 
Kestenbaum 200315;  
Schmiegelow 201416 
1.65 (1.28-2.11) 76% (46-89%) 
   Fixed effects model n/a 1.39 (1.29-1.49) 85% (70-93%) 
Coronary 
Heart Disease 
GH in 1st pregnancy 
   Excluding study(s) with the largest effect Riise 201838 1.40 (1.17-1.66) 73% (10-92%) 
   Fixed effects model n/a 1.35 (1.25-1.45) 74% (27-91%) 
A history of GH 
   Excluding study(s) with the largest effect Tooher et al. 201713 1.49 (1.18-1.89) 78% (31-93%) 
   Fixed effects model n/a 1.39 (1.28-1.52) 88% (72-95%) 
Stroke 
GH in 1st pregnancy 
   Excluding study(s) with the largest effect Not conducted * - - - - 
   Fixed effects model n/a 1.19 (1.06-1.32) 82% (44-94%) 
A history of GH 
   Excluding study(s) with the largest effect Not conducted * - - - - 
   Fixed effects model n/a 1.33 (1.17-1.51) 70% (0-91%) 
Heart Failure A history of GH 
   Excluding study(s) with the largest effect Not conducted * - - - - 
   Fixed effects model n/a 1.75 (1.57-1.95) 63% (0-90%) 
CI – Confidence Intervals; GH – Gestational Hypertension; RR – Relative Risk 
















RR (95% CI) I2 (95% CI) P-value 
GH in 1st pregnancy 
Level of Adjustment 
Adequately/Well 5 1.38 (1.26-1.52) 91% (83-96%) 
0.796 
Poor 2 1.60 (1.50-1.72) 82% (53-93%) 
Risk of Bias 
Low Risk 5 1.51 (1.42-1.60) 93% (87-96%) 
0.904* 
Not Low Risk 2 1.75 (1.43-2.14) 94% (82-98%) 
Average follow-up 
<20 years 4 1.63 (1.53-1.74) 93% (86-96%) 
0.281 
>20 years 3 1.21 (1.08-1.36) 63% (0-92%) 
Year of Publication 
Up to 2010 3 1.50 (1.32-1.71) 80% (35-94%) 
0.781 
2010 onwards 4 1.53 (1.44-1.62) 96% (92-98%) 
Population 
European 5 1.61 (1.51-1.71) 91% (81-95%) 
0.694* 
Non-European 2 1.20 (1.06-1.36) 95% (83-98%) 
A history of GH 
Level of Adjustment 
Adequately/Well 3 1.34 (1.24-1.46) 87% (64-96%) 
0.417 
Poor 4 1.41 (1.21-1.65) 82% (53-93%) 
Risk of Bias 
Low Risk 4 1.31 (1.21-1.43) 66% (1-88%) 
0.656* 
Not Low Risk 4 1.50 (1.29-1.74) 91% (76-96%) 
Average follow-up 
<20 years 3 2.40 (1.77-3.27) 0% (0-90%) 
0.475 
>20 years 5 1.31 (1.22-1.42) 83% (57-93%) 
Year of Publication 
Up to 2010 3 1.28 (1.08-1.52) 89% (56-97%) 
0.863 
2010 onwards 5 1.37 (1.27-1.48) 83% (61-93%) 
Population 
European 3 1.27 (1.18-1.38) 70% (0-91%) 
0.303* 
Non-European 5 1.90 (1.58-2.28) 72% (20-90%) 
CI – Confidence Intervals; GH – Gestational Hypertension; RR – Relative Risk; N - Number 








Figure S1. Association between gestational hypertension in a woman’s first pregnancy and 
subsequent risk of cardiovascular events in unadjusted analyses.  
 









Figure S2. Association between a history of one or more pregnancies affected by gestational 
hypertension and subsequent risk of cardiovascular events in unadjusted analyses. 
 









Figure S3. Association between a history of one or more pregnancies affected by gestational 
hypertension and subsequent risk of any stroke event in adjusted analyses. 
 









Figure S4. Funnel plot of the studies contributing to the meta-analysis of the risk of 
cardiovascular disease after gestational hypertension in the first pregnancy. 
 
Egger’s test p-value: 0.682. Vertical dashed lines indicate the confidence intervals from the pooled 




































Figure S5. Funnel plot of the studies contributing to the meta-analysis of cardiovascular 
disease risk after a history of one or more pregnancies affected by gestational hypertension. 
  
Egger’s test p-value: 0.051. Trim-and-fill estimate: RR=1.26 (1.15-1.39). Vertical dashed lines indicate 
































Figure S6. Funnel plot of the studies contributing to the meta-analysis the risk of any stroke 
event after a history of one or more pregnancies affected by gestational hypertension. 
 
Egger’s test p-value: 0.382. Vertical dashed lines indicate the confidence intervals from the pooled 
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